top of page
Key publications from the Macauley Lab
Insulin, insulin signaling, and AD
Slow wave sleep and abeta
image
Screen%20Shot%202020-03-30%20at%208
Aerobic glycolysis and AD
sleep caitlin
CC acute paper
Biorxiv
Macauley_graphical abstract_glib
jci insight
katp slide
kir6.2 story graph abstract
ev paper
EV graph abs
Screen Shot 2020-03-30 at 8.07.09 PM
Hyperglycemia and Abeta
Hyperinsulinemia and abeta
Publications (full list)

  1. Macauley SL, Horsch AD, Otterdoom M, Zheng MH, Stewart GR.  The effects of transforming growth factor-beta-2 on dopaminergic graft survival.  Cell Transplant. 2004;13(3):245-52.
     

  2. Sleat DE, Wiseman JA, El-Banna M, Kim KH, Mao Q, Price S, Macauley SL, Sidman RL, Shen MM, Zhao Q, Passini MA, Davidson BL, Stewart GR, Lobel P.  A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.  J Neurosci. 2004 Oct 13;24(41):9117-26.
     

  3. Shihabuddin LS, Numan S, Huff MR, Dodge JC, Clarke J, Macauley SL, Yang W, Taksir TV, Parsons G, Passini MA, Gage FH, Stewart GR.  Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology.  J Neurosci. 2004 Nov 24;24(47):10642-51.
     

  4. Passini MA, Macauley SL, Huff MR, Taksir TV, Bu J, Wu IH, Piepenhagen PA, Dodge JC, Shihabuddin LS, O'Riordan CR, Schuchman EH, Stewart GR.  AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease.  Mol Ther. 2005 May;11(5):754-62.
     

  5. Griffey M, Macauley SL, Ogilvie JM, Sands MS.  AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther. 2005 Sep;12(3):413-21.
     

  6. Lin D, Donsante A, Macauley SL, Levy B, Vogler C, Sands MS.  CNS-directed AAV2/5-mediated gene therapy synergizes with myeloreductive BMT in the murine model of globoid-cell leukodystrophy. Mol Ther. 2007 Jan;15(1):44-52.
     

  7. Kielar C., Maddox L, Bible E, Pontikis CC, Macauley SL, Griffey MA, Wong M, Sands MS, and Cooper JC. Neuron loss occurs in the thalamus before the cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis. 2007 Jan;25(1):150-62.
     

  8. Macauley SL*, Sidman RL, Taksir TV, Schuchman EH, Stewart GR.  Investigation of the structure-functional relationship in mouse model of Niemann-Pick A Disease.  Exp. Neurol.  2008 Dec; 214(2):181-92. *Corresponding Author
     

  9. Macauley SL and Sands MS. Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases. Exp. Neurol. 2009 Nov; 18(21).
     

  10. Macauley SL, Wozniak D, Kielar C, Tang Y, Cooper JD, and Sands MS.  Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1 deficient mouse.  Exp. Neurol.  2009 May;217(1):124-35.
     

  11. Kielar C, Wishart TM, Palmer A, Dihanich S, Macauley SL, Sands MS, Pearce DA, Cooper JD, Gillingwater TH. Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease. Hum. Mol. Genet. 2009 Nov 1;18(21):4066-80.
     

  12. Reddy AS, Kim J,  Hawkins-Salsbury J, Macauley SL, Tracy E, Vogler C, Han X, Song SK, Wozniak D, Fowler SC, Klein R, and Sands MS. Bone marrow transplantation augments the effect of brain- and spinal cord-directed AAV2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy J Neurosci. 2011 Jul 6;31(27):9945-57.
     

  13. Macauley SL, Pekny M, Sands MS.  The role of astrocyte activation in a mouse model of infantile neuronal ceroid lipofusciniosis. J Neurosci. 2011 Oct 26;31(43):15575-85.
     

  14. Roberts MS*, Macauley SL*, Roberts MS, Wong A, Yilmas D, Hohm S, Cooper J, and Sands MS.  Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis.  2012 Sep;35(5):847-57.  *Co-first authors
     

  15. Macauley SL, Roberts MS, Wong A, Reddy AS, Cooper J, and Sands MS.  Bone marrow transplantation dramatically increases the therapeutic benefit of CNS-directed AAV2/5 mediated gene therapy in infantile neuronal ceroid lipofuscinosis.  Ann Neurol.  2012 Jun;71(6):797-804.
     

  16. Macauley SL, Wong AMS, Shyng C, Augner DP, Dearborn JT, Pearse Y, Roberts MS, Fowler SC, Cooper JD, Watterson DM, and Sands MS.  An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci. 2014 Sep 24;34(39):13077-82.
     

  17. Macauley SL and Holtzman DM.  Recent advances from the bench toward the bedside in Alzheimer’s disease.  EBioMedicine.  2015 Feb;2(2): 94-95.
     

  18. Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, Perez R, Mahan TE, Sutphen CL, Holtzman DM. Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. J Clin Invest. 2015 Jun;125(6):2463-7.
     

  19. Harris RA, Tindale L, Lone A, Singh O, Macauley SL, Stanley M, Holtzman DM, Bartha R, and Cumming RC.  Aerobic glycolysis in the frontal cortex correlates with memory performance in wild-type mice but not the APP/PS1 mouse model of cerebral amyloidosis. J. Neurosci.  2016 Feb 10;36(6):1871-8.
     

  20. Macauley SL.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem. Pediatr Endocrinol Rev. 2016 Jun 13; 1:639-48.
     

  21. Stanley M, Macauley SL, and Holtzman DM. Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? J Exp Med. 2016 Jul 25;213(8):1375-85. 
     

  22. Stanley M, Macauley SL, Caesar EE, Koscal LJ, Moritz W, Robinson GO, Roh J, Keyser J, Jiang H, and Holtzman DM. The effects of peripheral and central high insulin on brain insulin signaling and amyloid-beta in young and old APP/PS1 mice. J Neurosci. 2016 Nov 16;36(46):11704-11715.
     

  23. Shyng C, Macauley SL, Dearborn JT, and Sands MS.  Widespread expression of a membrane-tethered version of the soluble lysosomal enzyme palmitoyl protein thioesterase-1. JIMD Rep. 2017 Feb 18.
     

  24. Ju Y S, Ooms SJ, Sutphen C, Macauley SL, Zangrilli M, Jerome G, Fagan AM, Mignot E, Zempel JM, Claasssen JAHR, and Holtzman DM.  Slow wave sleep disruption increased cerebrospinal fluid amyloid-beta levels.  Brain. 2017 Aug 1;140(8):2104-2111.
     

  25. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018 Mar;14(3):168-181.
     

  26. Day SE, Yang W, Stern J, Zhou X, Macauley SL, and Ma T. Glucagon-like peptide-1 cleavage product improves cognitive function in a mouse model of Down syndrome.  eNeuro. 2019 Mar/Apr;6(2).
     

  27. Bashore AC, Liu M, Key CC, Boudyguina E, Wang X, Carroll CM, Sawyer JK, Mullick AE, Lee RG, Macauley SL, Parks JS. Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor. Arterioscler Thromb Vasc Biol. 2019 Jun 6;
     

  28. Kavanagh K, Day SM, Pait MC, Mortiz WR, Newgard CB, Ilkayeva O, McClain DA, Macauley SL. Type-2-diabetes Alters CSF but not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys. Front Neurosci. 2019 Aug 28;13:843.
     

  29. Carroll CM and Macauley SL. The interaction between sleep and metabolism in Alzheimer’s disease: cause or consequence of disease? Front Aging Neurosci. 2019 Sep 20;11:258.
     

  30. Damuka N, Czoty PW, Davis AT, Nader MA, Nader SH, Craft S, Macauley SL, Galbo LK, Epperly PM, Whitlow CT, Davenport AT, Martin TJ, Daunais JB, Mintz A, and Solingapuram Sai KK. PET imaging of [11C]MPC-6827, a microtubule-based radiotracer in non-human primate brains. Molecules. 2020 May 13;25(10):E2289.
     

  31. Gibson EM, Bennet FC, Gillespie SM, Guler AD, Gutmann DH, Halpern CH, Kucenas SC, Kushida CA, Lemieux M, Liddelow S, Macauley SL, Li TQ, Quinn M, Roberts, LW, Saligrama N, Taylor K, Venkatesh H, Yalcin B, and Zuchero JB. How support of early career researchers can reset science in the post-COVID19 world. Cell. June 2020.
     

  32. Frye BM, Craft S, Laitmer CS, Keene CD, Montine TJ, Register RC, Orr ME, Kavanagh K, Macauley SL, Shively CA. "Aging related Alzheimer's disease-like neuropathology and functional decline in captive vervet monkeys (Chlorocebus aethiops sabaeus). American Journal of Primatology. 2021. In press.
     

  33. Damuka N, Orr M, Czoty PW, Weiner JL, Martin TJ, Nader MA, Bansode AH, Liyana Pathirannahel BS, Mintz A, Macauley SL, Craft S, Solingapuram Sai KK. Effect of ethanol and cocaine on [11C]MPC-6827 uptake in SH-SY5Y cells. Mol Biol Rep. 2021   
     

  34. Damuka N, Orr ME, Bansode AH, Krizan I, Miller M, Lee J, Macauley SL, Whitlow CT, Mintz A, Craft S, Solingapuram Sai KK. Preliminary mechanistic insights of a brain-penetrant microtubule imaging PET ligand in a tau-knockout mouse model. EJNMMI Res. 2022 Jul 26;12(1):41. doi: 10.1186/s13550-022-00912-z. PMID: 35881263
     

  35. Macauley SL*, Grizzanti J, Stanley M, Caesar EE, Mortiz WR, Bice AR, Cruz-Diaz N, Carrol CM, Day SM, Constantino NJ, Mahan TE, Snipes JA, Orr TC, Culver JP, Remedi MS, Nichols CG, Karch CM, Cox LA, Diz DI, Bauer AQ, Holtzman DM. Sulfonylureas target the neurovascular response to decrease Alzheimer’s pathology. BioRxiv. doi: https://doi.org/10.1101/2021.08.11.455969
    **In revision at Journal of Clinical Investigation (impact factor = 14.81) *Corresponding Author
     

  36. Rosene MJ, Hsu S, You SF, Brase L, Verbeck A, Martinez R, Wallace CE, Li A, Yan P, Drager NM, Sattler SM, Iyer AK, Macauley SL, Holtzman DM, Benitez BA, Kampmann M, Cruchaga C, Harari O, Cirrito JR, Lee JM, Goate AM, Karch CM. Phospholipase D3 contributes to Alzheimer’s disease risk via disruption of Aβ clearance and microglia response to amyloid plaques. MedRxiv. doi: https://doi.org/10.1101/2022.01.31.22270175
     

  37. Day SM, Gironda SC, Clarke CW, Snipes JA, Nicol NI, Kamran H, Vaughan W, Weiner JL, Macauley SL. Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice. Neurobiol Dis. 2023 Feb;177:105967. doi: 10.1016/j.nbd.2022.105967. Epub 2022 Dec 16. PMID: 36535550.
     

  38. Ma T, Chang RCC, Macauley SL. Editorial: Metabolic signaling dysregulation and cognitive impairments in aging and Alzheimer’s disease. Front. Aging Neurosci. 2023 Feb 23; 15.
     

  39. Grizzanti J, Moritz WR, Pait MC, Stanley M, Kaye SD, Carroll CM, ConstantinoNJ, Deitelzweig LJ, Snipes JA, Kellar D, Caesar EE, Pettit-Mee RJ, Day SM, Sens JP, Nicol NI, Dhillon J, Remedi MS, Kiraly DD, Karch CM, Nichols CG, Holtzman DM, Macauley SL. KATP channels are necessary for glucose-dependent increases inamyloid-β and Alzheimer's disease-related pathology. JCI Insight. 2023 May 2;8(10):e162454. doi: 10.1172/jci.insight.162454. PMID: 37129980; PMCID: PMC10386887.
     

  40. Carroll CM, Stanley M, Raut RV, Constantino NJ, Irmen RE, Mitra A, Snipes JA, Raichle ME, Holtzman DM, Gould RW, Kishida KT, and Macauley SL. Acute hyper- and hypo-glycemia uncouples the metabolic cooperation between glucose and lactate to disrupt sleep. bioRxiv 2022.09.15.507967; doi: https://doi.org/10.1101/2022.09.15.507967  **Under review at J Neurosci
     

  41. Lee S, Williams HC, Gorman AA,  Devanney NA, Harrison DA, Walsh AE, Goulding DS, Tuck T, Schwartz JL, Zajac DJ, Macauley SL, Estus S, TCW J, Johnson LA,  Morganti JM. APOE4 drives transcriptional heterogeneity and maladaptive immunometabolic responses of astrocytes. bioRxiv 2023.02.06.527204; doi: https://doi.org/10.1101/2023.02.06.527204 
     

  42. Pait MC, Kaye SD, Su Y, Kumar A, Singh S, Gironda SC, Vincent S, Anwar M, Carroll CM, Snipes JA, Lee J, Furdui CM, Deep G, Macauley SL. Novel method for collecting hippocampal interstitial fluid extracellular vesicles (EVISF) reveals sex-dependent changes in microglial EV contents in response to Aβ pathology. bioRxiv, https://doi.org/10.1101/2023.03.10.532133 **In revision at Journal of Extracellular Vesicles (Impact Factor = 25.84).  
     

  43. Ruggiero AD, Vemuri R, Blawas M, Long M, DeStephanis D, Williams AG, Chen H, Justice JN, Macauley SL, Day SM, Kavanagh K. Long-term dasatinib plus quercetin effects on aging outcomes and inflammation in nonhuman primates: implications for senolytic clinical trial design. Geroscience. 2023 Jun 1. doi: 10.1007/s11357-023-00830-5. Epub ahead of print. PMID: 37261678.
     

  44. Carroll CM*, Irmen RE*, Constantino NJ, Snipes JA, Vincent S, McArdle C, Gould RW, Macauley SL. Differential impacts of amyloid beta and tau pathology on sleep and metabolic functioning. In preparation. *Co-First Authors
     

  45. Carroll CM, Constantino NJ, Irmen RE, Snipes JA, Vincent S, McArdle C, Gould RW, Macauley SL. Peripheral metabolism bidirectionally modulates slow wave sleep in a model of Alzheimer’s disease. In preparation.
     

  46. Rhea EM, Leclerc M, Yassine HM, Capuano AW, Tong H, Petyuk VA, Macauley SL, Fioramonti X, Carmichael O, Calon F, and Arvanitakis Z. State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer’s Disease. Aging and Disease. 2023. http://dx.doi.org/10.14336/AD.2023.0814

Select Meeting Abstracts

  1. Numan S, Huff MR, Macauley SL, Ziegler R, Cheng S, Stewart GR.  Optimizing viral vector-based gene therapy to the brain: a comparative study of intracranial delivery systems and approaches. Society for Neuroscience Meeting, New Orleans, LO, 2000.
     

  2. Macauley SL, Otterdoom M, Horsch AD, Zheng M, Stewart GR.  The effects of TGF-β on dopaminergic graft survival.  American Society for Neural Transplantation and Repair Meeting, Coldwater, FL, 2001.
     

  3. Macauley SL, Shihabuddin LS, Schuchman, EH, Mervis RF, Taksir T, Stewart GR.  Neuropathology of Niemann-Pick A (ASMKO) mouse.  Society for Neuroscience Meeting, Orlando, FL, 2002.
     

  4. Stewart GR, Schuchman, Macauley SL.  Behavioral pathology of the Niemann-Pick A (ASMKO) mouse: structure-function studies on Purkinje cell degeneration.  Society for Neuroscience Meeting, Orlando, FL, 2002.
     

  5. Switzer III RC, Macauley SL, Schuchman EH, Griffey M, Sands M, Stewart GR.  Comparative pathology of neurometabolic disease animal models using silver degeneration staining: Infantile Batten (PPT1), Krabbe (twitcher), and Niemann-Pick A (ASMKO). Society for Neuroscience Meeting, Orlando, FL, 2002. 
     

  6. Passini MA, Macauley SL, Huff MR, Taksir TV, Yew NS, O’Riordan CR, Schuchman EH, Stewart GR.  Widespread gene delivery and reversal of pathology in the brains of Niemann-Pick A mice by retrograde axonal transport of a therapeutic AAV vector.  Society for Neuroscience Meeting, New Orleands, LO, 2003.
     

  7. Shihadbuddin LS, Huff MR, Macauley SL, Clarke J, Parsons G, Taksir TV, Gage FH, Stewart GR.  Intracerebral transplantation of adult mouse neural progenitor cells into Niemann-Pick A mouse leads to marked decrease in storage deposits. Society for Neuroscience Meeting, New Orleans, LO, 2003.
     

  8. Zhao Q, Macauley SL, Raben N, Mattaliano R, Stewart GR.  Neuropathology in a muscle-wasting disase: observations from the 6neo/neo mouse model of Pompe Disease. Society for Neuroscience Meeting, San Diego, CA, 2004.
     

  9. Macauley SL, Ness JK, Lee C, Snider BJ, Green SH, Sands MS, Goldberg MP.  Lentiviral vector expression of GFP in cultured oligodendrocytes. Society for Neuroscience Meeting, San Diego, CA, 2004.
     

  10. Macauley SL, Griffey M, Bible E, Vogler C, Wong M, Rothman S, Wozniak D, Cooper J, Sands MS. Chronic inflammation and its contribution to neurodegeneration in Batten disease: Implications for therapy.  Society for Neuroscience Meeting, Washington, DC, 2005.
     

  11. Macauley SL, Vogler C, Wozniak D, and Sands MS.  The relationship between cerebellar pathology and motor deficits in the PPT1-/- mouse model of INCL. International Council on Batten Disease, Rochester, NY 2007.
     

  12. Macauley SL, Reddy AS, Pekny M, and Sands MS.  The role of astrocyte activation in an inherited model of neurodegenerative disease.  Glia in Health & Disease Meeting, Cold Spring Harbor, NY 2008.
     

  13. Macauley SL, Roberts MS, and Sands MS.  Combination therapy for the treatment of infantile neuronal ceroid lipofuscinosis (INCL).  American Society of Gene & Cell Therapy Meeting, Washington, DC, 2010.
     

  14. Macauley SL, Roberts MS, Hohm SA, Reddy AS, Cooper JD, and Sands MS.  Therapeutic approaches for the treatment of infantile neuronal ceroid lipofuscinosis.  WORLD symposium, Las Vegas, NV.  2011.
     

  15. Macauley SL, Yamada SA, Stanley M, Perez R, Mahan TE, and Holtzman DM. The effects of systemic hyperglycemia on amyloid-beta levels within brain interstitial fluid. Keystone Conference, CO, 2014.
     

  16. Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, Perez R, Mahan TE, and Holtzman DM.  Hyperglycemia modulates extracellular amyloid-beta levels and neuronal activity in vivo.  AD/PD, Nice, France, 2015.
     

  17. Macauley SL, Caesar EE, Stanley M, Mortiz WR, Mahan TE, and Holtzman DE.  Chronic treatment with sulfonylurea, glyburide, reduces amyloid-beta pathology in the APPswe/PSEN1dE9 mouse model of Alzheimer’s disease.  American Diabetes Association Meeting, June 2016, New Orleans, LA.
     

  18. Pait M, Moritz WR, Carroll CM, Stanley M, Winkey K, Hollingsworth C, Remedi MS, Yuede CM, Nichols C, Holtzman DM, and Macauley SL. In vivo deletion of Kir6.2 in a APP/PS1 mouse model abolishes hyperglycemic increase in interstitial fluid amyloid-beta but does not affect brain plaque burden. Society for Neuroscience, San Diego, CA, 2018.
     

  19. Carroll CM, Stanley M, Pait M, Hollingsworth C, Holtzman DM, and Macauley SL. The effect of glycemic changes on brain metabolism and sleep/wake in vivo using biosensor technology. Society for Neuroscience, San Diego, CA, 2018.
     

  20. Kumar JSD, Kim J, Castrillon J, Molotkov A, Dileep H, Duff K, Scneider N. Macauley SL, Craft S, Milligan C, Mann JJ, Mintz A, and Solignapuram Sai KK. In vivo evaluation of microtubule PET ligand [11C]MPC-6827 in animal models of neurodegenerative disorders.  Society of Nuclear Medicine & Molecular Imaging, Anaheim, CA, 2019.
     

  21. Carroll CM, Stanley M, Rubinow D, Golias C, Holtzman, DM, Macauley SL. Effect of glycemic extremes on sleep/wake and Alzheimer’s disease pathophysiology. Sleep 2019, San Antonio, TX, 2019.
     

  22. Solingapuram Sai KK, Whitlow CT, Kumar JSD, Craft S, Mintz A, Macauley SL. In Vivo Evaluations of Microtubule-Based PET Radiotracer, [11c]MPC-6827 in Murine Models of Alzheimer's Disease. Alzheimer’s Association International Conference, Los Angelos, CA, 2019.
     

  23. Day SM, Pait M, Mortiz WR, Newgard C, Ilkayeva O, McClain D, Kavanagh K, Macauley SL. Type-2-diabetes Alters CSF but not plasma metabolomic and AD risk profiles in vervet Monkeys. Society for Neuroscience, Chicago, IL, 2019.
     

  24. Rubinow DA, Sink S, Odelade A, Golias C, Snipes A, Day SM, McClain DA, Han J, Macauley SL. Genetic and Dietary Iron Overload in the Pathogenesis of Type-2-Diabetes and Alzheimer’s Disease. Society for Neuroscience, Chicago, IL, 2019.
     

  25. Cruz-Diaz, N, Snipes A, Diz D, Macauley SL. Glyburide treatment improves aortic arch pulse wave velocity in a murine model of Alzheimer’s disease. American Heart Association virtual meeting, 2020.
     

  26. Pait MC, Su Y, Snipes JA, Deep G, Macauley SL. Alzheimer’s-related pathology modulates exosomes in the hippocampal interstitial fluid. Alzheimer’s Association International Conference: Neuroscience Next, 2020.
     

  27. Carroll CM, Stanley M, Macauley SL. The relationship between disrupted metabolism and sleep is altered by the presence of amyloid-beta pathology. Alzheimer’s Association International Conference: Neuroscience Next, 2020.
     

  28. Grizzanti J, Karch CM, Cox LA, Holtzman DM, Macauley SL. Systemic glyburide treatment normalizes aberrant gene expression in female APP/PS1 mice. Alzheimer’s Association International Conference: Neuroscience Next, 2020.
     

  29. Day SM, Macauley SL. Alcohol use disorder as a risk factor for Alzheimer’s disease. Alzheimer’s Association International Conference: Neuroscience Next, 2020.
     

  30. Deitelzweig LJ, Pait MC, Carroll CM, Yuede CM, Holtzman DM, Macauley SL. Elucidating the link between Alzheimer’s Disease and Type 2 Diabetes: Kir6.2-/- APP/PS1 exhibit behavioral deficits without an increase in amyloid-beta plaque load. Alzheimer’s Association International Conference: Neuroscience Next, 2020.

bottom of page